Soluble cytokine receptors: novel immunotherapeutic agents

Bibliography

• PAUL WE: Pleiotropy and redundancy of T cell derivedlymphokines in the immune responses. Cell (1989) 57:521–524.
   PubMed Web of Science ®Google Scholar
• ARAI K, LEE F, MIYAJIMA A, MIYATAKE S, ARM N,YOKOTA T: Cytokines: coordinators of immune and inflammatory responses. Ann. Rev. Biochem. (1990) 59:783–836.
   PubMed Web of Science ®Google Scholar
• OPPENHEIM JJ, SAKLATVALA J: Cytokines and theirreceptors. In: Clinical applications of cytokines: role in pathogenesis, diagnosis and therapy. Oppenheim JJ, Rossio J, Gearing AJH (Eds.), Oxford University Press, New York (1993):3–15.
   Google Scholar
• JANEWAY CA, TRAVERS P: Immunobiology. The immune system in health and disease. In: Current Biology Garland Publishing, London (1996).
   Google Scholar
• FERNANDEZ-BOTRAN R: Soluble cytokine receptors: basic immunology and clinical applications. Crit. Rev. Clin. Lab. Sci. (1999) 36:165–224.
   PubMed Web of Science ®Google Scholar
• •A recent review on the basic properties and applications of soluble cytokine receptors.
   Google Scholar
• RUBIN LA, KURMAN CC, FRITZ ME et al.: Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J. Immunol (1985) 135:3172–3177.
   PubMed Web of Science ®Google Scholar
• HEANEY ML, GOLDE DW: Soluble receptors in human disease. J. Leukocyte Biol. (1998) 64:135–146.
   PubMed Web of Science ®Google Scholar
• ADERKA D: The potential biological and clinical signifi-cance of the soluble tumor necrosis factor receptors. Cyt. Growth Factor Rev. (1996) 7:231–240.
   PubMedGoogle Scholar
• MORELAND LW: Clinical and pharmacological experi-ence with etanercept. Exp. Opin. Invest. Drugs (1999) 8:1443–1451.
   PubMedGoogle Scholar
• ••A very complete review on the basic properties, pharma-cology and clinical experience with etanercept in RA.
   Google Scholar
• SMITH CA, FARRAH T, GOODWIN RG: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell (1994) 76:959–962.
   PubMed Web of Science ®Google Scholar
• GEARING AJH, BECKETT P, CHRISTODOULOU M et al.: Processing of tumor necrosis factor-a precursor by metalloproteinases. Nature (1994) 370:555–557.
   PubMed Web of Science ®Google Scholar
• MOSLEY B, BECKMAN MP, MARCH CJ et al.: The murine Interleukin-4 receptor: molecular cloning and charac-terization of secreted and membrane bound forms. Cell (1989) 59:335–348.
   PubMed Web of Science ®Google Scholar
• •Original report on the cloning of the murine IL-4R and the discovery of a separate message encoding a soluble form of the receptor.
   Google Scholar
• HORIUCHI S, KOYANAGI Y, ZHOU Y et al.: Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur. J. Immunol. (1994) 24:1945–1948.
   PubMed Web of Science ®Google Scholar
• GOODWIN RG, FRIEND D, ZIEGLER SF et al.: Cloning of the human and murine interleukin-7 receptors: Demonstration of a soluble form and homology to a new receptor superfamily. Cell (1990) 60:941–951.
   PubMed Web of Science ®Google Scholar
• LOWENTHAL JW, GREENE WC: Contrasting interleukin-2 binding properties of the a (p55) and 13 (p70) protein subunits of the human high affinity interleukin-2 receptor. J. Exp. Med. (1987) 166:1156–1161.
   PubMed Web of Science ®Google Scholar
• TAVERNIER J, DEVOS R, CORNELIS S et al.: A human highaffinity interleukin-5 receptor (11512) is composed of an 11-5-specific a chain and a 13 chain shared with the receptor for GM-CSF. Cell (1991) 66:1175–1184.
   PubMed Web of Science ®Google Scholar
• •A report on the cloning of the IL-5R and a soluble IL–5R.
   Google Scholar
• TAGA T, KISHIMOTO T: Cytokine receptors and signal transduction. FASEB J (1993) 6:3387–3396.
   Web of Science ®Google Scholar
• IHLE JN, WITTHUHN BA, QUELLE FW, YAMAMOTO K,SILVENNOINEN 0: Signalling through the hemato-poietic cytokine receptors. Ann. Rev. Immunol. (1995) 13:369–398.
   PubMed Web of Science ®Google Scholar
• TAGA T, KISHIMOTO T: gp130 and the interleukin-6family of cytokines. Ann. Rev. Immunol (1997) 15:797–819.
   PubMed Web of Science ®Google Scholar
• •A review on the IL-6 family of cytokines and their signal transduction.
   Google Scholar
• TRINCHIERI G: Interleukin-12: a proinflammatorycytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann. Rev. Immunol. (1995) 13:251–276.
   PubMed Web of Science ®Google Scholar
• TREIGER BF, LEONARD WJ, SVETLIK P, RUBIN LA,NELSON DL, GREENE WC: A secreted form of the human interleukin-2 receptor encoded by an 'anchor minus' cDNA. j Immunol (1986) 136:4099–4105.
   PubMed Web of Science ®Google Scholar
• DAYER, JM, BURGER D: Interleukin-1, tumor necrosisfactor and their specific inhibitors. Eur. Cyt. Netw. (1994) 5:563–571.
   PubMed Web of Science ®Google Scholar
• SATO TA, WIDMER MB, FINKELMAN FD et al: Recombi-nant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J. Immunol. (1993) 150:2717–2723.
   PubMed Web of Science ®Google Scholar
• ••A very interesting report on the ability of sIL-4R to eitherinhibit or potentiate the activity of IL-4 in vivo.
   Google Scholar
• HALE KK, SMITH CG, BAKER SL et al.: Multifunctionalregulation of the biological effects of TNF-a by the soluble Type I and Type II TNF receptors. Cytokine (1995) 7:26–38.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-BOTRAN R, VITETTA ES: Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J. Exp. Med. (1991) 174:673–681.
   PubMed Web of Science ®Google Scholar
• MOHLER KM, TORRANCE DJ, SMITH CA et al: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antago-nists. J. Immunol. (1993) 151:1548–1561.
   PubMed Web of Science ®Google Scholar
• ••This manuscript reports on the use of sTNFR II:Fc hybridprotein in a murine sepsis model and on its carrier and inhibitor properties.
   Google Scholar
• ADERKA D, ENGELMANN H, MAOR Y, BRAKEBUSCH C.WALLACH D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. (1992) 175:323–329.
   Google Scholar
• MA Y, HURST HE, FERNANDEZ-BOTRAN R: Soluble interleukin-4 receptors as carrier proteins: their effects on the pharmacokinetics of murine IL-4 in vivo. J. Pharmacol Exp. Ther. (1996) 279:340–350.
   PubMed Web of Science ®Google Scholar
• •Analysis of the effects of a soluble receptor (IL-4R) on the pharmacokinetics of its ligand (IL–4).
   Google Scholar
• FINKELMAN FD, MADDEN KB, MORRIS SC et al.: Anti-cytokine antibodies as carrier proteins. Prolonga-tion of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J. Immunol. (1993) 151:1235–1244.
   Google Scholar
• AKIRA S, HIRANO T, TAGA T, KISHIMOTO T: Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J (1990) 4:2860–2867.
   PubMed Web of Science ®Google Scholar
• VAN DER POLL T, VAN DEVENTER SJH: Cytokines and anticytokines in the pathogenesis of sepsis. Infect. Dis. N Amer. (1999) 13:413–427.
   PubMed Web of Science ®Google Scholar
• ••A review with valuable insight into the balance of pro- andanti-inflammatory cytokines in sepsis and the effects of cytokine inhibitors.
   Google Scholar
• PAUWELS RA, BRUSSELLE GG, TOURNOY KG, LAMBRECHT BN, KIPS JC: Cytokines and their receptors as therapeutic targets in asthma. Clin. Exp. Allergy (1998) 28\(Suppl. 3):1–5.
   Google Scholar
• •A review discussing the potential targeting of cytokines of cytokine receptors in asthma.
   Google Scholar
• RUBIN LA, NELSON DL: The soluble interleukin-2 receptor: biology, function and clinical application. Ann. Intern. Med. (1990) 113:619–627.
   PubMed Web of Science ®Google Scholar
• ESTROV Z, KURZROCK R, ESTEY E et al.: Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood (1992) 79: 1938-1945.
   Google Scholar
• SOLORZANO CC, KAIBARA, A, HESS PJ et al.: Pharma-cokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. J. Appl. Physiol (1998) 84:1119–1130.
   PubMed Web of Science ®Google Scholar
• CHRISTEN U, THUERKAUF R, LESSLAUER W: Immune response to a recombinant human TNER55-IgG1 fusion protein: autoantibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities. Human Immunol (1999) 60:774–790.
   PubMed Web of Science ®Google Scholar
• JACOBS CA, LYNCH DH, ROUX E et al.: Characterizationand pharmacokinetic parameters of recombinant soluble interleukin-4 receptor. Blood (1 9 9 1) 77:2396-2403.
   Google Scholar
• JACOBS CA, BECKMANN MP, MOHLER K, MALISZEWSKI CR, FANSLOW WC, LYNCH DH: Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Int. Rev. Exp. Pathol. (1993) 34 Pt B:123–135.
   Google Scholar
• KeRSCHNER C, GAROTTA G, DEMBIC Z: Construction, purification, and characterization of new interferon y (IFNy) inhibitor proteins. J. Biol. Chem. (1992) 267:9354–9360.
   PubMed Web of Science ®Google Scholar
• RICHTER, WF, GALLATI H, SCHILLER CD: Animalpharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab. DisposiL (1999) 27:21–25.
   PubMed Web of Science ®Google Scholar
• BEUTLER BA: The role of tumor necrosis factor inhealth and disease. J. Rheumatol. (1999) 26\(Suppl. 5 7):16-21. A concise review on TNF and its biology.
   Google Scholar
• PESCHON J, TORRANCE DS, STOCKING KL et al.: TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. (1998) 160:943–952.
   PubMed Web of Science ®Google Scholar
• EVANS TJ, MOYES D, CARPENTER A et al.: Protective effect of 55 kD but not 75 kD soluble TNF receptor-IgG fusion proteins in an animal model of Gram-negative sepsis. J. Exp. Med. (1994) 180:2173–2179.
   PubMed Web of Science ®Google Scholar
• •A study comparing the activities of sTNFR-I and sTNFR-II in an experimental sepsis model.
   Google Scholar
• COLAGIOVANNI DB, SHOPP GM: Evaluation of interleukin-1 receptor antagonist (IL-1RA) and tumor necrosis factor binding protein (TNF-BP) in a rodent abcess model of host resistance. Immunopharmacol. Immunotoxicol (1996) 18:397–419.
   PubMed Web of Science ®Google Scholar
• MCCOMB J, GOULD T, CHLIPALA E et al.: Antiarthriticactivity of soluble tumor necrosis factor receptor Type I forms in adjuvant arthritis: correlation of plasma levels with efficacy. J. Rheumatol (1999) 26:1347–1351.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, CHARLES P, TAYLOR P, MAINI RN: Biological insights from clinical trials with anti-TNF therapy. Springer Semin. Immunopathol. (1998) 20:211–228.
   PubMed Web of Science ®Google Scholar
• ••A review on the results obtained with anti-TNF therapies inRA.
   Google Scholar
• LESSLAUER W, TABUCHI H, GENTZ R et al: Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur. j Immunol. (1991) 21:2883–2886.
   PubMed Web of Science ®Google Scholar
• SOLORZANO CC, KSONTINI R, PRUITT JH et al: Involve-ment of 26-kDa cell-associated TNFa in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J. Immunol. (1997) 158:414–419.
   PubMed Web of Science ®Google Scholar
• WELBORN MB, DOUGLAS WG, ABOUHAMZE A et al:Visceral ischemia-reperfusion injury promotes tumor necrosis factor (TM') and interleukin-1 (IL-1) dependent organ injury in the mouse. Shock (1996) 6:171–176.
   PubMed Web of Science ®Google Scholar
• DENTS M, GUOJIAN L, WIDMER M, CANTIN A: A mousemodel of lung injury induced by microbial products: implication of tumor necrosis factor. Am. J. Resp. Cell Mol. Biol. (1994) 10:658–664.
   PubMed Web of Science ®Google Scholar
• SUFFREDINI AF, REDA D, BANKS SM, TROPEA M, AGOSTIJM, MILLER R: Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J. Immunol. (1995) 155:5038–5045.
   PubMed Web of Science ®Google Scholar
• FISHER JR CJ, AGOSTI JM, OPAL SM et al.: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The soluble TNF receptor sepsis study group. N Engl. J. Merl. (1996) 334:1697–1702.
   Google Scholar
• ABRAHAM E, GLAUSER MP, BUTLER T et al: p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro-45-2081 Study Group. JAMA (1997) 277:1531–1538.
   Google Scholar
• ABRAHAM, E: Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med. (1999) 25:556–566.
   PubMed Web of Science ®Google Scholar
• ••A review discussing the potential causes for the apparentfailure of anti-TNF therapies in sepsis.
   Google Scholar
• PIGUET PF, GRAU GE, VESIN C, LOETSCHER H, GENTZ R,LESSLAUER W: Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology (1992) 77:510–514.
   PubMed Web of Science ®Google Scholar
• WOOLEY PH, DUTCHER J, WIDMER MB, GILLIS S: Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on Type II collagen-induced arthritis in mice. J. Immunol. (1993) 151:6602–6607.
   PubMed Web of Science ®Google Scholar
• NAM MH, REDA D, BOUJOUKOS AJ, AGOSTI J, SUFFRE-DINI AF: Recombinant human chimeric tumor necrosis factor (TNF) receptor (TNFR:Fc): Safety and pharmacokinetics in humans. Clin. Res. (1993) 41:249A.
   Google Scholar
• MORELAND, LW, MARGOLIES GR, HECK LW et al.: Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. (1996) 23:1849–1855.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.:Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl. J. Med. (1997) 337:141–147.
   PubMed Web of Science ®Google Scholar
• •Report describing the exciting results of a clinical trial with etanercept in RA patients.
   Google Scholar
• MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al. Etanercept therapy in rheumatoid arthritis. Ann. Intern. Merl. (1999) 130:478–486.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. J. Med. (1999) 340:253–259.
   PubMed Web of Science ®Google Scholar
• •Study of the therapeutic effects of combination therapy with etanercept and methotrexate.
   Google Scholar
• LOVELL DJ, GIANNINI EH, WHITMORE JB et al.: Safety and efficacy of tumor necrosis factor receptor p75 fusion protein (TNFR:Fc, Enbrel) in polyarticular course juvenile rheumatoid arthritis (RA). Arthritis Rheum. (1998) 41 (Suppl.):S470.
   Google Scholar
• SANDER 0, DEN BROEDER A, VAN DER HOOGEN F: Thirty month treatment with a TNFa receptor-fusion protein (TNER55-IgGl, R045-2081) in patients with severe refractory RA. Arthritis Rheum. (1997) 40:S81.
   Google Scholar
• DESWAL A, BOZKURT B, SETA Y et al.: Safety and efficacyof a soluble p75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 99:3224–3226.
   PubMed Web of Science ®Google Scholar
• KLINKERT WE, KOJIMA K, LESSLAUER W, RINNER W, LASSMANN H, WEKERLE H: TNF-a receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview. J. Neuroimmunol. (1997) 72:163–168.
   PubMed Web of Science ®Google Scholar
• THE LENERCEPT MULTIPLE SCLEROSIS STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: TNF neutralization in MS. Results of a randomized, placebo-controlled multicenter study. Neurology (1999) 53:457–465.
   Google Scholar
• PAUL WE: Interleukin-4: A prototypic immunoregulatory lymphokine. Blood (1991) 77: 1627-1652.
   Google Scholar
• IDZERDA RL, MARCH CJ, MOSLEY B et al. Human interleukin 4 receptor confers biological responsive-ness and defines a novel receptor superfamily. J. Exp. Med. (1990) 171:861–873.
   PubMed Web of Science ®Google Scholar
• KONDO M, TAKESHITA T, ISHII N et al. Sharing of theinterleukin-2 (IL-2) receptor y chain between receptors for11-2 and11-4. Science (1993) 262: 1874-1877.
   Google Scholar
• HILTON DJ, ZHANG JG, METCALF D, ALEXANDER WS, NICOLA NA, WILSON TA: Cloning and characterization of a binding subunit of the interleukin-13 receptor that is also a component of the interleukin-4 receptor. Proc. Natl. Acad. Sci. USA (1996) 93:497–501.
   PubMed Web of Science ®Google Scholar
• FANSLOW WC, CLIFFORD KN, PARK LS et al.: Regulation of alloreactivity in vivo by 11-4 and the soluble 11-4 receptor. J. Immunol. (1991) 147:535–540.
   PubMed Web of Science ®Google Scholar
• GESSNER A, SCHROPPEL K, WILL A, ENSSLE KH, LAUFFER L, ROLLINGHOFF M: Recombinant soluble interleukin-4 (1-4) receptor acts as an antagonist of IL-4 in murine cutaneous leishmaniasis. Infect. Immunol. (1994) 62:4112–4117.
   PubMed Web of Science ®Google Scholar
• ••Important manuscript demonstrating that therapy withsIL-4R may change the phenotype of the immune response from Th2 to Thl.
   Google Scholar
• PUCCETTI P, MENCACCI A, CENCI E eta].: Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J. Infect. Dis. (1994) 169:1325–1331.
   Google Scholar
• GARRONE P, DJOSSOU 0, GALIZZI JP, BANCHEREAU J: A recombinant extracellular domain of the human interleukin 4 receptor inhibits the biological effects of interleukin 4 on T and B lymphocytes. Eur. J. Immunol. (1991) 21:1365–1369.
   PubMed Web of Science ®Google Scholar
• ENSSLE K, LAUFFER L, KANZY EJ et al.: Solubleinterleukin-4 receptors inhibit 11-4 driven prolifera-tion and IgE production by PBMNC of atopic children and counteract human TH2-like cells from the site of allergy. Immunobiology (1993) 189:132–142.
   Google Scholar
• BORISH L, NELSON H, NATHAN B et al.: Phase I nebuliza-tion study of recombinant human IL-4 receptor (rhuIL-4R) in adult patients with mild atopic asthma. J. Allergy Clin. Immunol (1997) 99:S413. Abstract 1678.
   Google Scholar
• BORISH L, NELSON HS, LANZ M, CLAUSSEN LR, MARTINDW, GARRION L: Phase I/II study of interleukin-4 receptor (IL-4R) in moderate asthma. J. Allergy Clin. Immunol. (1998) 101:S8-S9. Abstract 35.
   Google Scholar
• SCHORLEMMER HU, LAUFFER L, KANZY EJ, ENSSLE K: Immunoregulation by recombinant interleukin-4 receptor (IL-4R) of murine GvH and SLE-like diseases in BDF1 hybrid mice and MRL/Ipr autoimmune mice. Agents Actions (1994) 41 (Spec. Conf. Issue):C180–C182.
   Google Scholar
• AREND WP: Inhibiting the effects of cytokines inhuman diseases. Adv. Intern. Med. (1995) 40:365–394.
   PubMedGoogle Scholar
• SIMS JE, GAYLE MA, SLACK JL et al.: Interleukin 1signaling occurs exclusively via the Type I receptor. Proc. Natl. Acad. Sci. USA (1993) 90:6155–6159.
   PubMed Web of Science ®Google Scholar
• COLOTTA F, RE F, MUZIO M et al.: Interleukin-1 Type IIreceptor: a decoy target for IL-1 that is regulated by 11-4. Science (1993) 261:472–475.
   PubMed Web of Science ®Google Scholar
• SVENSON M, HANSEN MB, HEEGAARD P, ABELL K, BENDTZEN K: Specific binding of interleukin 1 (L1-1)6 and IL-1 receptor antagonist (11-lra) to human serum. High-affinity binding of 11-lra to soluble 11-1 receptor Type I. Cytokine (1993) 5:427–435.
   Google Scholar
• SYMONS JA, YOUNG PR, DUFF GW: Soluble Type II interleukin 1 (IL-1) receptor binds and blocks processing of11-113 precursor and loses affinity for11-1 receptor antagonist. Proc. Natl. Acad. Sci. USA (1995) 92:1714–1718.
   PubMed Web of Science ®Google Scholar
• DOWER SK, WIGNALL JM, SCHOOLEY K et al: Retention of ligand binding activity by the extracellular domain of the 11-1 receptor. J. Immunol (1991) 142:4314–4320.
   Web of Science ®Google Scholar
• JACOBS CA, BAKER PE, ROUX ER et al.: Experimental autoimmune encephalomyelitis is exacerbated by IL-la and suppressed by soluble IL-1 receptor. J. Immunol. (1991) 148:2983–2989.
   Google Scholar
• SCHORLEMMER HU, KANZY EJ, LANGNER KD, KURRLE R: Immunomodulatory activity of recombinant IL-1 receptor (IL-1-R) on models of experimental rheuma-toid arthritis. Agents Actions (1993) 39 (Spec. Conf. Issue):C113–C116.
   Google Scholar
• FANSLOW WC, SIMS JE, SASSENFELD H et al.: Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science (1990) 248:739–742.
   PubMed Web of Science ®Google Scholar
• DREVLOW BE, LOVIS R, HAAG MA et al.: Recombinant human interleukin-1 receptor Type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. (1996) 39:257–265.
   PubMed Web of Science ®Google Scholar
• MULLARKEY MF, LEIFERMAN KM, PETERS MS et al.: Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor. J. Immunol. (1994) 152:2033–2041.
   PubMed Web of Science ®Google Scholar
• LUST JA, JELINEK DF, DONOVAN KA et al.: Sequence,expression and function of an mRNA encoding a soluble form of the human interleukin-6 receptor (sIL-6R). Curr. Top. Microbiol. Immunol. (1995) 194:199–206.
   PubMedGoogle Scholar
• NARAZAKI M, YASUKAWA K, SAITO T et al.: Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood (1993) 82:1120–1126.
   PubMed Web of Science ®Google Scholar
• •Report of the existence of soluble forms of the gp130 subunit and their ability to block IL-6 signalling.
   Google Scholar
• SCHOBITZ B, PEZESHKI G, POHL T et al.: Soluble interleukin-6 (1-6) receptor augments central effects of 11-6 in vivo. FASEB J (1995) 9:659–664.
   PubMed Web of Science ®Google Scholar
• •Report dealing with the potentiation of IL-6 activity by the soluble IL–6R.
   Google Scholar
• GAILLARD JP, LIAUTARD J, KLEIN B et al.: Major role of the soluble interleukin-6/interleukin-6 receptor complex in the proliferation of interleukin-6-dependent human myeloma cell lines. Eur. J. Immunol (1997) 27:3332–3340.
   PubMed Web of Science ®Google Scholar
• CARROLL G, BELL M, WANG H, CHAPMAN H, MILLS J: Antagonism of the IL-6 cytokine subfamily - a potential strategy for more effective therapy in rheumatoid arthritis. Inflamm. Res. (1998) 47:1–7.
   PubMed Web of Science ®Google Scholar
• •An interesting review on the potential therapeutic use of inhibitors of IL-6 and related cytokines, particularly in RA.
   Google Scholar
• YOSHIZAKI K, NISHIMOTO N, MIHARA M, KISHIMOTO T: Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Sem. Immunopathol. (1998) 20:247–259.
   PubMed Web of Science ®Google Scholar
• SANDERSON CJ, CAMPBELL HD, YOUNG IG: Molecularand cellular biology of eosinophil differentiation factor (interleukin-5) and its effects on human and mouse B cells. Immunol Rev. (1988) 102:29–50.
   PubMed Web of Science ®Google Scholar
• CLARK SC, KARMEN R: The human hematopoietic colony-stimulating factors. Science (1987) 236:1229–1237.
   PubMed Web of Science ®Google Scholar
• MONFARDINI C, KIEBER-EMMONS T, VONFELDT JM et al.:Rational design, analysis, and potential utility of GM-CSF antagonists. Proc. Assoc. Amer. Phys. (1996) 108:420–431.
   PubMedGoogle Scholar
• BROWN CB, BEAUDRY P, LAING TD, SHOEMAKER S, KAUSHANSKY K: In vitro characterization of the human recombinant soluble granulocyte-macrophage colony-stimulating factor receptor. Blood (1995) 85:1488–1495.
   PubMed Web of Science ®Google Scholar
• BACH EA, AGUET M, SCHREIBER RD: The IFN-gamma receptor: a paradigm for cytokine receptor signaling. Ann. Rev. Immunol. (1997) 15:563–591.
   PubMed Web of Science ®Google Scholar
• OZMEN L, GRIBAUDO G, FOUNTOULAKIS M, GENTZ R, LANDOLFO S, GAROTTA G: Mouse soluble IFNy receptor as IFNy inhibitor. Distribution, antigenicity, and activity after injection in mice. J. Immunol (1993) 150:2698–2705.
   Google Scholar
• OZMEN L, ROMAN D, FOUNTOULAKIS M, SCHMID G, RYFFEL B, GAROTTA G: Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-y receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. (1995) 25:6–12.
   PubMed Web of Science ®Google Scholar